Canada Approves Pfizer Covid Shot for Adolescents
(Bloomberg) -- Canada became one of the first countries to approve the use of the Pfizer Inc.-BioNTech SE Covid-19 vaccine for adolescents as young as 12.
The shot was initially approved in December for those 16 and older. The decision by the country's public-health officials comes ahead of a similar clearance that is expected soon from regulators in the U.S. It allows Prime Minister Justin Trudeau's government to expand its vaccination campaign to adolescents.
Canada's inoculation effort has lagged its peers in the Group of Seven. The nation has administered at least one dose to 29.7% of its population, according to the Bloomberg Vaccine Tracker, compared to 44.5% in the U.S. and 51.9% in the U.K.
“After completing a thorough and independent scientific review of the evidence, the department has determined that this vaccine is safe and effective at preventing Covid-19 when used in children between 12 and 15 years of age,” Health Canada said in a statement Wednesday.
The New York-based company said at the end of March it's vaccine was 100% effective in a final-stage trial in kids ages 12 to 15, a finding that opened the door to getting regulatory approval for teens and pre-teens before the start of the next school year.
“We are proud that we are playing a part of the efforts to help protect adolescent Canadians in this devastating pandemic,” Fabien Paquette, vaccine lead at Pfizer Canada, said in a news release.
White House chief medical adviser Anthony Fauci said Wednesday the Food and Drug Administration is likely to issue an emergency authorization for use of the shot in U.S. adolescents in the near future.
“I think it is going to be very soon,” Fauci told NBC News. “I don't want to get ahead of the FDA, but I believe it is going to be within several days. I cannot imagine it is going to be much longer than that.”
| More on Covid-19 in Canada: |
|---|
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.